Talphera (TLPH) Q2 2024 earnings summary

Executive summary

• NEPHRO study for Niyad/nafamostat is progressing, with multiple sites screening patients and FDA approval to expand to 14 U.S. clinical sites; final site initiations are scheduled for this month.

• Dr. Pam Palmer, co-founder and CMO, will retire in October but will continue advising until NEPHRO study completion and potential FDA approval; Dr. Shakeel Aslam joined as Chief Development Officer.

• Focus remains on developing and commercializing innovative therapies for medically supervised settings, with lead candidates Niyad and LTX-608 targeting anticoagulation and critical care.

• Divested DSUVIA to Alora in April 2023, retaining rights to certain milestone and sales-based payments, and monetized a portion via an $8.0 million agreement with XOMA in January 2024.

• Net loss for Q2 2024 was $3.8 million, improved from prior year periods.

Financial highlights

• Closed Q2 2024 with $14.0 million in cash, cash equivalents, and investments, up from $9.4 million at year-end 2023.

• Q2 cash operating expenses (R&D and SG&A, excluding stock-based compensation) totaled $4.0 million, up from $3.8 million year-over-year.

• Net loss for Q2 2024 was $3.8 million, compared to $4.4 million in Q2 2023; net loss per share was $0.15, improved from $0.40 in Q2 2023.

• Annual cash operating expense guidance reduced to $19–$21 million from $21–$23 million.

• Financing activities provided $12.0 million in H1 2024, mainly from the XOMA agreement and a $6.0 million private placement.

Outlook and guidance

• Enrollment at high-volume sites expected to accelerate NEPHRO study progress; updated study completion and PMA filing timeline to be provided next quarter.

• Commercial launch preparations for Niyad underway, pending FDA approval; peak sales estimate for Niyad in hospitals is $100 million, with outpatient dialysis potentially adding another $100 million.

• Management expects to need additional capital to fund operations within twelve months, given current cash resources and planned expenditures.

• Breakthrough Device Designation from FDA may expedite potential approval of nafamostat in 2025.

• Focus remains on completing the Niyad registrational trial and evaluating timing for pre-filled syringe product NDA submissions.